Novavax trial success; New Vaccine approved by the MHRA

4 Feb 2022

In an effort to tackle the COVID-19 pandemic, 15,000 people across the UK, including 545 Exeter locals, were recruited to take part in the phase 3 trial for Nuvaxovid™, the Novavax COVD-19 vaccine in only five and a half weeks.

The trial was supported by over 100 healthcare staff from across the Royal Devon & Exeter NHS Foundation Trust, the Patient Recruitment Centre Exeter and the NIHR Clinical Research Facility: Exeter, as well as staff from other organisations including the University of Exeter, University of Plymouth, NIHR CRN South West Peninsula and local GP’s.

Two years on and Nuvaxovid™ has now been approved by the MHRA as the first protein-based vaccine option to be administered for 1st and 2nd doses, to help fight against the COVID-19 pandemic.

Dr Ray Sheridan, Consultant Physician and Principal Investigator explains that “due to the different nature of this protein-based vaccine, it’s much easier to store, which in turn makes it easier to transport and use in other countries where this is currently an issue. the vaccine is now being manufactured in the UK and millions of doses will be used to supply countries worldwide - We are all safer when we are all vaccinated!

“The overwhelmingly positive response from the public in signing up to take part was essential to the local success of this study – So a big “thank you” to the participants for volunteering and to the many NHS staff who worked on this incredible health advance.

“It’s excellent news that the NOVAVAX vaccine has now received MHRA approval for use in the United Kingdom. Now we have a fifth vaccine that provides high protection against COVID-19 with really positive immune responses and a very reassuring safety profile; The public can be assured it’s been rigorously assessed through clinical trials and by the MHRA.”

For more information on Nuvaxovid™, you can view the product information leaflet on the GOV.UK website.



Our site uses cookies to help give you a better experience. By continuing to use it you consent to the use of cookies as set out in our privacy policy.